TABLE 4.

Diagnostic performance of methylation-specific PCR in stool specimens with the Ct value and ML as indicators ^a .

Marker	Indicator	Specificity (%)	Sensitivity (%)	AUC	AUC 95% CI	Group
SDC2	Ct	99.30	44.20	0.64	0.57 to 0.71	Adenoma vs. normal
TFPI2	Ct	100.00	67.40	0.85	0.81 to 0.89
SDC2/TFPI2	Ct	95.70	80.00	0.87	0.81 to 0.92
SDC2	Ct	100.00	78.60	0.88	0.85 to 0.92	Cancer vs. normal
TFPI2	Ct	100.00	88.80	0.95	0.93 to 0.97
SDC2/TFPI2	Ct	96.40	96.60	0.98	0.96 to 0.99
SDC2	Ct	54.70	81.60	0.69	0.63 to 0.75	Cancer vs. adenoma
TFPI2	Ct	32.60	90.80	0.63	0.59 to 0.70
SDC2/TFPI2	Ct	64.20	73.80	0.72	0.67 to 0.78
SDC2	ML	73.20	45.30	0.51	0.42 to 0.59	Adenoma vs. normal
TFPI2	ML	89.90	71.60	0.78	0.70 to 0.84
SDC2/TFPI2	ML	89.90	71.60	0.78	0.72 to 0.85
SDC2	ML	86.20	56.80	0.72	0.66 to 0.77	Cancer vs. normal
TFPI2	ML	89.90	78.60	0.86	0.82 to 0.90
SDC2/TFPI2	ML	88.40	82.00	0.87	0.84 to 0.90
SDC2	ML	75.80	53.40	0.67	0.61 to 0.72	Cancer vs. adenoma
TFPI2	ML	71.60	55.30	0.63	0.56 to 0.69
SDC2/TFPI2	ML	73.70	52.90	0.67	0.62 to 0.74

^aML = 2^−ΔΔCt, in which ΔΔCt = (Ct _target - Ct _ACTB )_sample - (Ct _target - Ct _ACTB )_{positive control}.